NCT02502968View on ClinicalTrials.gov

BL-8040 Addition to Consolidation Therapy in AML Patients

PHASE2UnknownINTERVENTIONAL

Enrollment

194

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

July 31, 2018

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Cytarabine

DRUG

BL-8040

DRUG

Placebo (for BL-8040)

Powder for solution for injection manufactured to mimic BL-8040

Trial Locations (1)

06120

RECRUITING

Univeritätsklinikum Halle, Klinik Innere Medizin 4, Halle

Sponsors

Collaborators (1)

BioLineRx, Ltd.

All Listed Sponsors

collaborator

BioLineRx, Ltd.

INDUSTRY

lead

Dr. Petra Tschanter

OTHER

NCT02502968 - BL-8040 Addition to Consolidation Therapy in AML Patients | Biotech Hunter | Biotech Hunter